کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2485389 1114354 2012 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Stavudine
موضوعات مرتبط
علوم پزشکی و سلامت داروسازی، سم شناسی و علوم دارویی اکتشاف دارویی
پیش نمایش صفحه اول مقاله
Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Stavudine
چکیده انگلیسی
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate-release (IR) solid oral dosage forms containing stavudine (d4T) are reviewed. According to Biopharmaceutics Classification System (BCS), d4T can be assigned to BCS class I. No problems with BE of IR d4T formulations containing different excipients and produced by different manufacturing methods have been reported and, hence, the risk of bioinequivalence caused by these factors appears to be low. Furthermore, d4T has a wide therapeutic index. It is concluded that a biowaiver is appropriate for IR solid oral dosage forms containing d4T as the single active pharmaceutical ingredient (API) provided that (a) the test product contains only excipients present in the IR d4T drug products that have been approved in a number of countries for the same dosage form, and (b) both test product and its comparator are either “very rapidly dissolving” or “rapidly dissolving” with similarity of dissolution profiles demonstrated at pH 1.2, 4.5, and 6.8. © 2011 Wiley Periodicals, Inc. and the American Pharmacists Association.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Pharmaceutical Sciences - Volume 101, Issue 1, January 2012, Pages 10-16
نویسندگان
, , , , , , , , ,